BusinessDeciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate HighlightsBy Nasdaq OMXNov 14, 2017, 12:00 PM UTC
BusinessCytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell TransplantationBy Nasdaq OMXNov 14, 2017, 11:00 AM UTC
BusinessCORRECTING and REPLACING -- Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian CancerBy Nasdaq OMXNov 14, 2017, 12:23 AM UTC
BusinessArbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)By Nasdaq OMXNov 13, 2017, 10:22 PM UTC
BusinessCelsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian CancerBy Nasdaq OMXNov 13, 2017, 10:15 PM UTC
BusinessVascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Patients With Persistent High Triglycerides and Chronic Kidney DiseaseBy Nasdaq OMXNov 13, 2017, 9:30 PM UTC
BusinessMacroGenics to Participate in Two Upcoming Investor ConferencesBy Nasdaq OMXNov 13, 2017, 9:01 PM UTC
BusinessCytokinetics Announces Additional Results From COSMIC-HF at the American Heart Association Scientific Sessions 2017By Nasdaq OMXNov 13, 2017, 7:10 PM UTC
